Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track records of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional banks, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 115,000 investors, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS investors have turned bullish on Eli Lilly
Increased sales from key drugs Cymbalta and Cialis -- the latter competes against Pfizer’s
On the down side, Eli Lilly's anchor antipsychotic drug Zyprexa continues to fare well, but it will face some new competition this year from generic versions of Johnson & Johnson’s
With current blockbusters going off patent, Eli Lilly wants to control costs and move drugs to market faster. This motivated a $1.6 billion deal with Covance and a recent boost to its animal health division by acquiring the Posilac cow hormone from Monsanto
To see what the very best CAPS analysts are saying now about Eli Lilly -- as well as other winning stocks they are picking -- head on over to CAPS and have a look.
More Foolishness: